Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure

Diabetes and Metabolism

Volumn 44, Issue 3, 2018, Pages 250-260

  Kimura, T ^a   Obata, A ^a   Shimoda, M ^a   Hirukawa, H ^a   Kanda Kimura, Y ^a   Nogami, Y ^a   Kohara, K ^a   Nakanishi, S ^a   Mune, T ^a   Kaku, K ^a   Kaneto, H ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Cell proliferation; Dulaglutide; Durability; GLP 1 receptor; cell

Indexed keywords

DULA; DULAGLUTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; FUSION PROTEIN; GLUCAGON LIKE PEPTIDE; IMMUNOGLOBULIN FC FRAGMENT; INSULIN; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; FIBROSIS; FOOD INTAKE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INFLAMMATION; INSULIN RELEASE; INSULIN SYNTHESIS; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; PROTECTIVE AGENTS; RECOMBINANT FUSION PROTEINS;

EID: 85042911235     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2017.10.007     Document Type: Article

References (19)

1. Kreymann, B., Williams, G., Ghatei, M.A., Bloom, S.R., Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987), 1300–1304.
2. Mojsov, S., Weir, G.C., Habener, J.F., Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79 (1987), 616–619.
3. Nauck, M., Stockmann, F., Ebert, R., Creutzfeldt, W., Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986), 46–52.
4. Ahren, B., Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab 39 (2013), 195–201.
5. Meier, J.J., Nauck, M.A., Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 59 (2010), 1117–1125.
6. Xu, G., Kaneto, H., Laybutt, D.R., Duvivier-Kali, V.F., Trivedi, N., Suzuma, K., et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycaemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56 (2007), 1551–1558.
7. Kimura, T., Kaneto, H., Shimoda, M., Hirukawa, H., Okauchi, S., Kohara, K., et al. Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol Cell Endocrinol 400 (2015), 78–89.
8. Kaneto, H., Obata, A., Shimoda, M., Kimura, T., Hirukawa, H., Okauchi, S., et al. Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs. Curr Med Chem 23 (2016), 3044–3051.
9. Heber, D., Dodson, R., Stoskopf, C., Peterson, M., Swerdloff, R.S., Pituitary desensitization and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone. Life Sci 30 (1982), 2301–2308.
10. Hou, S., Li, C., Huan, Y., Liu, S., Liu, Q., Sun, S., et al. Effects of E2HSA, a long-acting glucagon like peptide-1 receptor agonist, on glycaemic control and beta cell function in spontaneous diabetic db/db mice. J Diabetes Res, 2015, 2015, 817839.
11. Kitamura, T., Kido, Y., Nef, S., Merenmies, J., Parada, L.F., Accili, D., Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol 21 (2001), 5624–5630.
12. Kanda, Y., Shimoda, M., Hamamoto, S., Tawaramoto, K., Kawasaki, F., Hashiramoto, M., et al. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab 298 (2010), E278–E286.
13. Hamamoto, S., Kanda, Y., Shimoda, M., Tatsumi, F., Kohara, K., Tawaramoto, K., et al. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 15 (2013), 153–163.
14. Okauchi, S., Shimoda, M., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun 470 (2016), 772–782.
15. Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54 (2011), 1098–1108.
16. Tanabe, A., Kaneto, H., Kamei, S., Hirukawa, H., Shimoda, M., Kimura, T., et al. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic beta-cell function in subjects with type 2 diabetes mellitus. J Diabetes Complications 30 (2016), 1201–1203.
17. Conn, P.M., Crowley, W.F. Jr., Gonadotropin-releasing hormone and its analogues. N Engl J Med 324 (1991), 93–103.
18. Abu Hashim, H., Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights. Gynecol Endocrinol 28 (2012), 314–321.
19. He, L., Fong, J., von Zastrow, M., Whistler, J.L., Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108 (2002), 271–282.